Centrax

Quick links to important sections

Centrax

Method of action: Psycholeptics

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Centrax

Property Description
Active ingredient Prazepam
Form Capsules or Tablets
Pharmacological class Benzodiazepine
General purpose Anxiolytic (to relieve anxiety and tension)
Origin Synthetic

What Type of Medicine is Centrax and What is Its Active Ingredient?

Centrax is a trademark for the prescription-only medicine containing the active compound Prazepam, which is classified under the pharmacological class of benzodiazepines. Prazepam is a synthetic derivative, supplied primarily as capsules or tablets intended for oral administration. The drug is specifically recognized for its distinctive chemical structure that yields a single-active ingredient product. This composition is clinically recognized for its ability to target the central nervous system to mediate states of nervous tension.

What is the General Purpose and Form of Centrax?

The general purpose of Centrax is to exert a calming and stabilizing effect on the nervous system to relieve states of excessive anxiety and nervous tension. This action classifies it as an anxiolytic, which means its primary function is to alleviate anxiety. The formulation is primarily focused on addressing generalized anxiety, offering an approach to managing a persistently heightened state of arousal. Prazepam, like other benzodiazepines, is utilized for its capacity to reduce central nervous system excitability, thereby providing relief from hyperarousal. This medicine helps ease tension by modulating overactivity in the brain.

Why is Prazepam Considered a Long-Acting Drug?

Prazepam is distinguished as a long-acting agent due to its unique metabolic process, which is a key differentiating factor from alternatives. Upon absorption, the drug is rapidly converted into the active compound Nordiazepam (or Desmethyldiazepam). This secondary metabolite has an extended half-life, which contributes to a sustained therapeutic effect. This prolonged presence of the active substance in the body ensures consistent tension relief over an extended timeframe, a characteristic that supports its use in scenarios requiring prolonged action rather than immediate, short-term intervention.

What side effects are possible with Centrax?

Possible Side Effects and Safety Information

The official safety profile for Centrax (Prazepam) is primarily characterized by effects related to central nervous system (CNS) depression, as detailed in regulatory documents. Common and expected adverse reactions include daytime drowsiness, sedation, fatigue, and muscle weakness. Effects such as ataxia (impaired coordination) and dizziness are also frequently listed, particularly among older adult populations.

Regulatory agencies group adverse reactions into system-organ classes, with most effects categorized under Nervous System Disorders and Psychiatric Disorders. Less common effects may include visual disturbances and gastrointestinal complaints.

Serious Adverse Reactions and Safety Constraints

Official labeling documents serious risks, including profound sedation and respiratory depression, which are significantly heightened when Prazepam is combined with other CNS depressants, such as opioids or alcohol, potentially leading to coma or death. The label also documents the risk of developing physical and psychological dependence, with the likelihood increasing with higher doses and longer duration of use. Acute withdrawal reactions, which can be severe and life-threatening (including seizures and psychosis), are a documented risk upon abrupt cessation.

Use of Centrax is subject to specific constraints. It is contraindicated in individuals with pre-existing conditions such as severe hepatic insufficiency (due to the risk of hepatic encephalopathy), Myasthenia gravis, sleep apnoea syndrome, and severe respiratory insufficiency. Regulatory warnings also note that older adults are more susceptible to CNS depressant effects and the associated risk of falls.

Overdose and Emergency Response

Centrax Overdose and when to seek help

Overdose for Centrax (Prazepam) is defined by a spectrum of Central Nervous System (CNS) depressant effects. Regulatory documents mandate that patients seek immediate medical attention upon any suspected overdose. Emergency services must be contacted immediately if severe symptoms, such as trouble breathing, profound sedation, or loss of consciousness, are observed.

Documented Overdose Manifestations

Manifestations officially documented in regulatory information include somnolence (drowsiness), lethargy, ataxia (impaired coordination), confusion, and slurred speech. While overdose from Centrax alone is generally categorized as mild, the risk of severe toxicity and fatal outcome is significantly increased when taken concomitantly with other CNS depressants, notably alcohol or opioids. This co-ingestion is cited as a critical factor for escalation to severe outcomes, including respiratory depression and coma. Elderly patients and those with other health issues are noted to have an increased susceptibility to these CNS effects.

Management and Monitoring Requirements

Regulatory guidance emphasizes that professional management is centered on symptomatic and supportive treatment, including the maintenance of a patent airway and continuous monitoring of vital signs. Although the antidote Flumazenil is noted, its use is accompanied by regulatory cautions. Hospital observation may be required until the patient is stable and continuous monitoring is no longer necessary.

Therapeutic Uses of Centrax

What Centrax treats: Main Uses and Benefits

Prazepam is generally applied when anxiety is severe, disabling, or causing extreme distress, and is used in situations involving certain distressing symptoms. The medicine is commonly used to help manage symptoms related to excessive psychological tension and the pervasive worry associated with conditions such as Generalized Anxiety Disorder (GAD). It supports the patient during difficult episodes by helping ease the overall symptom burden, relevant for managing symptoms that interfere with daily comfort.

The medication is applied in clinical settings that involve acute or unstable symptom patterns, relevant when short-term symptomatic assistance is needed. This therapeutic scope is relevant for managing symptom clusters that interfere with daily comfort, including psychological tension, anxiety-related sleep disruption, and somatic symptoms of anxiety like muscle stiffness. The long-acting nature of Prazepam may offer supportive relief relevant for easing sustained tension, and may help maintain a sense of stability when symptoms are more noticeable during the treatment phase.


Quick Fact: Support for Excessive Psychological Tension


Regulatory References

  1. HPRA Summary of Product Characteristics for Centrax

Eligibility and Restrictions for Use

Centrax ( extbfPrazepam), a extbfbenzodiazepine, has strict eligibility requirements defined by regulatory authorities. Its use is limited to extbfadults for the short-term symptomatic treatment of severe anxiety and tension.

Contraindicated Populations (Must Not Use)

Centrax is extbfabsolutely contraindicated and must not be used by patients with the following conditions, as stated in the official labeling:

  • Severe Organ Insufficiency: Patients with extbfsevere hepatic insufficiency (liver failure) or extbfsevere respiratory insufficiency.
  • Neuromuscular/Sleep Disorders: Individuals with extbfMyasthenia Gravis or extbfSleep Apnoea Syndrome.
  • Hypersensitivity: Those with a known allergy to extbfPrazepam, any other extbfbenzodiazepine, or the product's excipients.
  • Excipient-Related: Patients with extbfrare hereditary problems such as galactose intolerance.

Restricted Use and Special Caution

Population/Condition Regulatory Status Constraint Details
Older Adults (Geriatric) Conditional Use Lower initial dose is recommended due to increased risk of extbfsedation and extbffalls.
Pediatric Population Not Recommended Use in extbfchildren and adolescents extbfunder 18 years is extbfnot recommended as safety and efficacy have not been established.
Hepatic/Respiratory Impairment Conditional Use extbfMild to moderate hepatic or extbfchronic respiratory insufficiency requires a extbfreduced dose and careful monitoring.
Pregnancy and Lactation Not Recommended Use is extbfnot recommended during extbfpregnancy or extbfbreastfeeding; the active substance is known to be excreted in breast milk.

Centrax is extbfnot recommended for the primary treatment of extbfpsychotic illness or extbfdepression (or anxiety associated with depression), and caution is mandatory for patients with a extbfhistory of alcohol or drug abuse.

What should I know about interactions with other medicines?

Centrax Interactions with other medicines and products

Interaction Scope Description in Official Documents
Interacting Drug Categories Opioid pain relievers, cough medicines containing opioids, alcohol, and other Central Nervous System (CNS) depressants.
Specific Interaction Mechanism The interaction is pharmacodynamic, resulting in an additive or potentiated CNS depressant effect when co-administered with other CNS depressants.
Associated Regulatory Restriction Co-administration with opioids has resulted in serious risks, including profound sedation, severe respiratory depression, coma, and death; this combination is subject to an FDA Boxed Warning.

Official regulatory information requires explicit precautions regarding the combined use of Centrax (as a benzodiazepine) with any product that causes CNS depression. This includes prescription opioids and over-the-counter medicines, illicit drugs, and alcohol. The primary concern is the increased risk of severe, life-threatening outcomes due to the additive effects on the central nervous system, particularly respiratory function. Healthcare professionals are advised to limit the dosage and duration of both Centrax and the concomitant CNS depressant to the minimum necessary when alternative treatment options are deemed inadequate. Co-administration should be strictly monitored. Additionally, Centrax, like other benzodiazepines, is primarily metabolized by the cytochrome P450 3A (CYP3A) enzyme system. Co-administration with potent CYP3A inhibitors (e.g., specific antifungals) can significantly increase Centrax plasma concentrations, which may lead to an increased risk of adverse reactions. Conversely, CYP3A inducers can decrease Centrax levels. These pharmacokinetic interactions necessitate careful clinical management to ensure safe and effective use.

Mechanism of Action

Centrax (prazepam) is a benzodiazepine that acts as a positive allosteric modulator of the GABA A receptor complex, the primary inhibitory neurotransmitter system in the central nervous system ( CNS).

GABA A Receptor Modulation

Centrax exerts its action by binding to a specific recognition site located at the interface of the alpha and gamma subunits on the postsynaptic GABA A receptor. This interaction does not directly activate the receptor but modifies its conformation, facilitating the effects of endogenous GABA. This allosteric engagement results in an increased frequency of chloride ion ( Cl^-) channel opening.

a GABA-A receptor showing the binding site for benzodiazepines and the


Modulation of Neuronal Excitability

The enhanced Cl^- conductance leads to a greater influx of negatively charged ions into the neuron, causing membrane hyperpolarization. This electrochemical change reduces the neuron's membrane potential and diminishes its overall excitability, resulting in a reduced neuronal firing probability. The molecular cascade modulates downstream neurotransmission and associated signaling sequences throughout the CNS pathways.

Dosage and Administration Information

How to Use Centrax

The usage of Centrax, which contains the active ingredient Prazepam, involves specific administration routes, dosing schedules, and durations of therapy. Centrax is intended solely for oral administration, typically supplied in tablet forms that may be scored and can be divided into equal doses for specific administration requirements.

Standard Usage and Duration

The standard daily dosing regimen for adults generally ranges from 20 mg to 40 mg daily, although up to 60 mg may be administered in more severe presentations. The medicine can be taken once daily, often as a single nightly dose to leverage its long-acting profile, or the total daily amount may be administered in divided doses.

A critical requirement for the use of Centrax is that the total treatment duration must be as short as possible. The use, including the necessary dose tapering-off process, must not exceed 4 to 6 weeks. This strict limit defines the medicine as a short-term therapeutic tool.

Population-Specific Use

Certain protocols apply for specific groups. Use is not recommended in children and adolescents under 18 years of age. For older adults and patients with hepatic or renal impairment, the initial dose must be small, often starting at half the standard adult dose, with a requirement for regular monitoring at the start of treatment to manage the risk of drug accumulation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Centrax (Prazepam)


Evidence for Short-Term Relief of Anxiety Symptoms

Centrax (Prazepam) was studied for its application in managing symptoms of excessive psychological tension and anxiety. Research has explored its use in conditions where symptoms may vary in intensity, such as Generalized Anxiety Disorder. The core evidence for this use was evaluated in numerous short-term Randomized Controlled Trials (RCTs), including studies comparing Centrax against an inactive placebo or other active anxiety medications. These trials examined the measured changes in anxiety symptoms over a defined, short period.

In these studies, researchers monitored changes in symptom intensity or variability using professional assessment tools. Findings describe patterns observed where participants reported short-term measurements of change in both the psychological and physical symptoms of anxiety, and studies often reported measured changes that differed from placebo control.

Evidence for the Long-Acting Pharmacokinetic Profile

Centrax was studied for its unique metabolic characteristics, which contribute to its classification as a compound studied for properties associated with long-acting characteristics. This research primarily involved pharmacokinetic (PK) studies conducted in healthy volunteers. The research describes that Prazepam is rapidly converted into the active compound, Nordiazepam.

Studies monitored the levels of this compound in the blood over time. Findings indicate that Nordiazepam has a prolonged half-life—the time it takes for its concentration to decrease by half. This is a chemical measure used to categorize the compound's extended presence. This evidence is primarily based on chemical and metabolic analysis rather than large-scale clinical outcome trials.


Long-Term Outcomes and Gaps in Research

When considering Centrax, it is important to understand the typical time frame of the existing research. The vast majority of the data regulators rely on was observed in trials lasting no more than 8 weeks, with the scope of assessing short-term or episodic symptom patterns.

There is limited information for long-term outcomes concerning the maintenance of symptom control or the overall course of conditions beyond a few months. Long-term effects are not fully established, and certainty remains low regarding the use of Centrax for extended periods. Furthermore, data for specific groups, such as very older adults or individuals with comorbidities, remain insufficient due to modest sample sizes and limited follow-up durations.

Frequently Asked Questions (FAQ)

Common questions about Centrax (FAQ)

Q: What is the main difference between Centrax and other medicines for the same condition?

Official information indicates that Centrax (Prazepam) is distinguished by its unique metabolism. It is rapidly converted in the body into an active compound called Nordiazepam, which has a prolonged half-life. This process results in a characteristic that is consistent with its long-acting classification.

Q: Is Centrax considered a narcotic or controlled substance?

Yes, Centrax is a prescription-only medicine that is classified as a Schedule IV controlled substance by regulatory agencies in the United States. This classification is due to its potential for abuse and dependence, which requires specific governmental controls.

Q: How long does it usually take to notice any effect from Centrax?

The onset of effect is generally described as slow for Centrax. This is because the body must first metabolize the original drug into its active form, Nordiazepam. This process supports its long-acting characteristics rather than providing immediate, short-term intervention.

Q: If I miss a dose of Centrax, what is the general recommendation?

According to the official patient information, the instruction is that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for your next scheduled dose, the official instruction is to skip the missed dose. The protocol is to resume the regular schedule and not take extra medicine to compensate.

Q: What does 'Centrax is indicated for X' mean in simple terms?

The term 'indicated for' means that Centrax has received formal approval from a regulatory authority to be used for a specific medical purpose. This approved purpose is the short-term symptomatic treatment of severe anxiety and tension.

Q: Are there any common foods or drinks that should be avoided when taking Centrax?

Official documents strictly advise against consuming alcohol while taking Centrax. This combination can lead to an additive CNS depressant effect, which carries a severe risk of profound sedation, respiratory depression, coma, and death.

Q: Can Centrax interact with common over-the-counter pain relievers?

Centrax is officially warned to interact with any pain relievers, including over-the-counter options, that contain opioids. Co-administration with opioids carries a Boxed Warning due to the severe risk of respiratory depression.

Q: Does Centrax need to be taken at a specific time of day?

Centrax can be taken once daily or the total amount can be divided into smaller doses. It is often described in regulatory documents as being administered as a single nightly dose to take advantage of the prolonged action of its active metabolite.

Q: Where can I find the official regulatory information for Centrax?

Official information, including the full prescribing details and patient leaflets, is publicly available on websites maintained by government regulatory bodies. Examples include the FDA’s DailyMed, the EMA’s SmPC database, Health Canada, and the MHRA.

Q: Why do some people need to take Centrax for different lengths of time?

The regulatory mandate requires that the total duration of treatment with Centrax, including the dose tapering process, must be as short as possible. The official constraint is that this duration generally should not exceed four to six weeks.

Q: Does Centrax come in different strengths or forms?

Centrax is supplied in tablet form. Official regulatory documents list 10 mg tablets as a primary strength. The dosage prescribed will fall within the officially approved range.

Q: What is the general success rate described in the studies for Centrax?

Research supporting Centrax focused on short-term randomized controlled trials (RCTs) to evaluate its use for anxiety symptoms. The data examined measured changes in anxiety symptoms over a defined, short period that were observed to differ from the placebo control group.

Q: Why is Centrax sometimes used together with another medicine?

While regulatory documents strictly warn about combining Centrax with central nervous system depressants, it may be used as part of a combination treatment plan in certain specialized cases. Any co-administration requires careful monitoring and dose limitation as defined in the official protocols.

Q: How is Centrax different from generic versions of the drug?

Centrax is the brand name for the active ingredient Prazepam. Generic versions contain the exact same active ingredient. Regulatory agencies require generic products to meet the same strict quality, strength, and effectiveness standards as the brand product.

Q: What kind of monitoring (like blood tests) is sometimes needed while on Centrax?

Official instructions require regular monitoring for specific populations, such as older adults and patients with hepatic (liver) or renal (kidney) impairment, particularly at the start of treatment. This often involves checking the function of those organs.

Q: Does taking Centrax with food change how it works?

Pharmacokinetic data for this class of medicine suggests that the presence of food in the stomach can potentially delay or reduce the absorption of the medicine into the bloodstream. This indicates that the initiation of the drug's effect may be slower.

Q: Is it true that Centrax requires a special prescription or monitoring?

Yes, Centrax is a prescription-only medicine and a controlled substance. Additionally, it requires regular monitoring for specific patient groups, such as older adults and individuals with organ impairment, as mandated by official labeling.

Q: Are there any known interactions between Centrax and herbal supplements?

Yes, official warnings cover interactions with Central Nervous System (CNS) depressants. Herbal supplements, such as kava or valerian root, that possess CNS depressant properties may increase the risk of adverse reactions when combined with Centrax.

Q: What information is included on the official Centrax Patient Information Leaflet?

The official Patient Information Leaflet (PIL) provides factual details on the medicine's approved purpose, correct administration, possible side effects, storage instructions, known interactions, and absolute contraindications. These leaflets are required by authorizing regulatory agencies.

Q: What is the difference between a side effect and an adverse reaction?

In regulatory documents, both terms refer to unintended effects of the medicine. Adverse reactions are grouped by seriousness and outcome, while side effects often refer to the expected, common, and predictable effects related to the medicine’s pharmacological action.

Q: Is Centrax considered a high-alert medication?

Regulatory agencies have placed stringent restrictions and warnings on Centrax, including a Boxed Warning for addiction, abuse, and withdrawal risk. This indicates the medicine requires a high level of regulatory and clinical oversight.

Q: What happens if Centrax is taken by someone who is not eligible for it?

Using the medicine when a specific condition is contraindicated carries a high risk of serious outcomes. For instance, official documents warn that use by a patient with severe hepatic insufficiency (liver failure) carries the potential risk of hepatic encephalopathy.

Q: Why are there different warnings for Centrax in different countries?

Regulatory agencies in different countries (like the FDA, EMA, or Health Canada) independently evaluate the available data. They establish warnings and use constraints that reflect their unique legal requirements, clinical standards, and assessment of the risk-benefit profile.

Q: Are there common misunderstandings about what Centrax is used for?

Yes, official warnings clarify that Centrax is not recommended for the primary treatment of psychotic illness or depression. Its purpose is specific to the short-term symptomatic treatment of severe anxiety and tension.

Q: Can Centrax be taken with common cold and flu medications?

Caution is required because many common cold and flu medications contain ingredients that are Central Nervous System (CNS) depressants, such as certain antihistamines or cough suppressants. Combining these with Centrax can lead to potentiated effects.

Q: Are there any official restrictions on the kind of work a person can do while taking Centrax?

Official documents warn that common side effects, such as drowsiness, dizziness, and impaired coordination (ataxia), may affect a patient's ability to drive or operate complex machinery. This restriction applies to professional activities requiring alertness and fine motor skills.

Q: Can Centrax be split or crushed, according to the official instructions?

Official documents state that Centrax tablets may be divided into equal doses because they may be scored. However, there is no official instruction permitting the tablet to be crushed.

How should Centrax be stored and disposed of?

The official storage and disposal instructions for Centrax (Prazepam) are mandated by regulatory agencies to maintain stability and ensure safety.

Storage Requirements

Centrax must be stored at controlled room temperature, typically between 20 C and 25 C. The medicine must be kept in its original container, which should be tightly closed to protect the contents from moisture.

Crucially, Centrax must be stored out of the sight and reach of children due to its classification as a potent central nervous system agent.

Disposal Instructions

To dispose of unused or expired Centrax, patients must not flush the medicine down a toilet or throw it in the household trash. Instead, the product should be returned to a pharmacist or a designated drug take-back program. Disposal must adhere to national and local controlled substance regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Centrax found in:

A-Z Index: